U.S. Food Stock News

OTCPK:CSBB
OTCPK:CSBBBanks

CSB Bancorp (OTCPK:CSBB) Loan Growth With Lower Non Performing Loans Challenges Risk Concerns

CSB Bancorp (CSBB) has put up a clean set of numbers for Q1 2026, with Q4 2025 revenue at US$9.5 million, basic EPS at US$0.71, and net income of US$1.9 million anchoring the latest run of results against a trailing year where earnings grew 33.5% and net profit margin sat at 30.2%. Over recent quarters, revenue has moved from US$9.1 million in Q4 2024 to US$11.0 million in Q1 2025, US$11.5 million in Q2 2025, US$12.3 million in Q3 2025, then US$9.5 million in Q4 2025, with EPS shifting from...
NYSE:ALK
NYSE:ALKAirlines

Alaska Air Group (ALK) Q1 Loss Of US$193m Tests Bullish Margin Expansion Narrative

Alaska Air Group (ALK) has opened 2026 with Q1 revenue of US$3.3b and a basic EPS loss of US$1.69, compared with a trailing twelve month basic EPS of US$0.63 on revenue of US$14.4b that produced net income of US$73m. Over recent quarters, revenue has moved from US$3.1b in Q1 2025 to US$3.6b in Q4 2025 before landing at US$3.3b in the latest period. Quarterly EPS has swung from a loss of US$1.35 in Q1 2025 to a profit of US$1.45 in Q2 2025 and back to a loss in Q1 2026, leaving investors...
NasdaqGS:NTRS
NasdaqGS:NTRSCapital Markets

Northern Trust (NTRS) Margin Compression To 20.7% Tests Bullish Efficiency Narrative

Northern Trust (NTRS) has opened Q1 2026 earnings season with a recent run of quarterly results that show total revenue moving from US$1,960.5 million in Q3 2024 to US$2,131.1 million in Q4 2025, alongside quarterly EPS stepping up from US$2.23 to US$2.44 over the same period. Over the last reported trailing twelve months to Q1 2026, revenue has ranged between US$7.9 billion and US$8.6 billion, with EPS running between about US$8.5 and US$10.8. This provides a basis for investors to weigh...
NYSE:MMM
NYSE:MMMIndustrials

3M (MMM) Margin Compression Reinforces Bearish Earnings Narrative Heading Into Q1 2026

3M (MMM) has just opened its Q1 2026 reporting season conversation with a recent run of results that saw quarterly revenue range from US$5.95 billion to US$6.52 billion through 2025, alongside basic EPS moving between US$1.08 and US$2.05 as net income fluctuated from US$577 million to US$1.12 billion. Over the same stretch, revenue has moved from US$6.01 billion in Q4 2024 to US$6.13 billion in Q4 2025, while basic EPS shifted from US$1.34 to US$1.08. This sets a backdrop where investors are...
NasdaqGS:BOKF
NasdaqGS:BOKFBanks

BOK Financial (BOKF) Net Margin Strengthens Community Narrative Of High Quality Earnings

BOK Financial (BOKF) opened 2026 with Q1 revenue of US$553.8 million and basic EPS of US$2.59, while trailing twelve month revenue sat at US$2.23 billion and EPS at US$9.88. This provides a clear snapshot of the bank's recent earnings power. Over the past year, revenue has moved from US$2.03 billion to US$2.23 billion and trailing twelve month EPS has gone from US$8.14 to US$9.88, giving investors a cleaner read on how the income statement is scaling. With net income on a trailing basis at...
NYSE:RTX
NYSE:RTXAerospace & Defense

RTX (RTX) Net Margin Expansion Tests Bullish Earnings Narrative Heading Into Q1 2026

RTX (RTX) opened the new year with Q1 2026 results coming on the heels of Q4 2025 revenue of US$24.2b and basic EPS of US$1.21, supported by Q4 net income of US$1.6b. Over the last six reported quarters, revenue moved from US$21.6b in Q4 2024 to US$24.2b in Q4 2025, while quarterly basic EPS ranged from US$1.10 to US$1.43. This sets up trailing twelve month EPS of US$5.02 and net income of US$6.7b as the reference point for today’s update, so the focus now is on how Q1 margins held up against...
NYSE:HAL
NYSE:HALEnergy Services

Halliburton (HAL) Net Margin Compression Challenges Bullish Earnings Growth Narratives

Halliburton (HAL) has just opened its books on the latest period, with trailing 12 month revenue most recently sitting at about US$22.2b and basic EPS shifting from US$2.84 a year ago to US$1.50 on the most recent trailing view, setting a very different earnings backdrop for investors to interpret. Over the last reported quarters, quarterly revenue has moved between US$5,417m and US$5,697m while basic EPS has ranged from US$0.02 to around US$0.70, giving a wide spread of earnings outcomes...
NasdaqGS:MBWM
NasdaqGS:MBWMBanks

Mercantile Bank (MBWM) Net Interest Margin Holds Near 3.5% Reinforcing Profitability Narratives

Mercantile Bank (MBWM) just posted another quarter of steady profitability, with Q4 2025 revenue at US$61.8 million and net income of US$22.8 million, which translates into basic EPS of US$1.40 ahead of its Q1 2026 reporting period. Over recent quarters the bank has seen revenue move from US$56.3 million in Q4 2024 to US$61.8 million in Q4 2025, while basic EPS increased from US$1.22 to US$1.40, giving investors a clear picture of consistent earnings power heading into the new year. With...
NYSE:OGN
NYSE:OGNPharmaceuticals

Organon (OGN) Is Up 8.4% After VTAMA Wins Key Steroid-Free Role In New Pediatric Guidelines

On April 15, 2026, Organon & Co. reported that VTAMA (tapinarof) cream received a strong, evidence-based recommendation in the American Academy of Dermatology’s first pediatric atopic dermatitis guidelines, which recognize it as the only steroid-free topical supported by high-certainty evidence for children aged 2 and older across all disease severities. This endorsement strengthens VTAMA’s clinical profile in a large pediatric eczema population, potentially reinforcing Organon’s...
NasdaqGS:ORIC
NasdaqGS:ORICBiotechs

A Look At ORIC Pharmaceuticals (ORIC) Valuation After New Rinzimetostat AACR Prostate Cancer Data

Why the AACR data on rinzimetostat is on investors’ radar ORIC Pharmaceuticals (ORIC) shares are in focus after the company highlighted new preclinical data for rinzimetostat at the 2026 AACR Annual Meeting, centered on prostate cancer models that include treatment resistant disease. See our latest analysis for ORIC Pharmaceuticals. ORIC’s latest AACR posters on rinzimetostat arrive after a strong year to date, with a 33.29% year to date share price return and a 123.61% 1 year total...
NasdaqGS:FLYW
NasdaqGS:FLYWDiversified Financial

Vertex And Two More Stocks Possibly Priced Below Their Estimated Worth

Over the last 7 days, the United States market has risen by 3.6%, and over the past year, it has seen a remarkable increase of 39%, with earnings forecasted to grow by 16% annually. In such a thriving environment, identifying stocks that are potentially undervalued can offer opportunities for investors looking to capitalize on discrepancies between current prices and estimated worth.
NYSE:DOUG
NYSE:DOUGReal Estate

3 Promising Penny Stocks With Market Caps Over $20M

Over the last 7 days, the United States market has risen 3.6%, and over the past year, it has climbed 39%, with earnings expected to grow by 16% annually. Penny stocks may be a throwback term, but they still offer intriguing opportunities for investors seeking growth at lower price points. By focusing on those with strong balance sheets and solid fundamentals, these stocks can present an underappreciated chance for stability and potential upside in today's market conditions.
NasdaqGS:RRBI
NasdaqGS:RRBIBanks

Discovering 3 Undiscovered Gems in the US Market

The United States market has experienced a notable upswing, climbing 3.6% over the last week and an impressive 39% over the past year, with earnings projected to grow by 16% annually. In such a dynamic environment, identifying stocks that are not only poised for growth but also remain under the radar can offer unique opportunities for investors seeking to capitalize on market momentum while discovering potential value.
NYSE:UHS
NYSE:UHSHealthcare

Is Universal Health Services (UHS) Offering Value After This Year’s Share Price Pullback?

Investors may be considering whether Universal Health Services offers good value at its current share price, or whether the recent share price move has already reflected much of the opportunity. The stock last closed at US$179.72, with a 1.9% decline over 7 days, a 3.3% decline over 30 days, an 18.3% decline year to date, and a 14.9% gain over the past year. Recent coverage has focused on Universal Health Services as a major player in US healthcare services, with ongoing attention on how...
NasdaqGM:OCUL
NasdaqGM:OCULPharmaceuticals

Ocular Therapeutix Data Strengthens AXPAXLI Durability Case And FDA Ambitions

Ocular Therapeutix (NasdaqGM:OCUL) released new 52-week post hoc Phase 3 data for AXPAXLI in wet age-related macular degeneration. The SOL-1 trial data indicated better durability, strong sustained disease control, and safety outcomes compared to aflibercept. The company presented the findings at a major ophthalmology conference and plans to seek FDA approval with a single pivotal Phase 3 trial. Ocular Therapeutix focuses on therapies for eye diseases, with AXPAXLI (OTX TKI) aimed at...
NYSE:WHR
NYSE:WHRConsumer Durables

Is It Time To Reassess Whirlpool (WHR) After Its Recent Share Price Rebound?

If you are wondering whether Whirlpool's current share price reflects its true worth, this breakdown will help you see how the market is pricing the business today. The stock last closed at US$57.25, with a recent 2.2% gain over 7 days and 9.5% over 30 days, set against a return of 23.2% decline year to date and 21.4% decline over the past year. Recent attention around Whirlpool has focused on its position in the household appliances market and how investors are weighing that against wider...
NYSE:HIMS
NYSE:HIMSHealthcare

3 Stocks That May Be Trading Below Their Estimated Intrinsic Value

The United States market has experienced a notable upswing, climbing 3.6% in the last week and rising 39% over the past year, with earnings projected to grow by 16% annually. In this environment, identifying stocks that may be trading below their estimated intrinsic value can present compelling opportunities for investors seeking to capitalize on potential market inefficiencies.
NYSE:ADC
NYSE:ADCRetail REITs

Agree Realty Dividend Hike Tests Sustainability Of Income Story

Agree Realty (NYSE:ADC) has approved increases to both its common and preferred dividends following board authorization. The updated payouts represent a change in the company’s dividend policy that is material for existing and prospective shareholders. These actions follow a period in which the stock has returned 10.3% year to date and 38.7% over 5 years, with the latest close at $79.56. For investors watching dividend income, Agree Realty’s new board-approved increases to both common and...
NasdaqGS:ATEC
NasdaqGS:ATECMedical Equipment

3 Growth Companies With High Insider Ownership Growing Earnings Up To 63%

The United States market has recently experienced a notable upswing, climbing 3.6% in the last week and showing a robust 39% increase over the past year, with earnings projected to grow by 16% annually in the coming years. In this favorable environment, growth companies with high insider ownership can be particularly appealing as they often demonstrate strong confidence from those who know the business best and have vested interests in its success.
OTCPK:LQMT
OTCPK:LQMTMetals and Mining

Vince Holding And 2 Other Promising Penny Stocks For Savvy Investors

The market has shown impressive growth, climbing 3.6% over the last week and 39% in the past year, with earnings forecasted to grow by 16% annually. While the term 'penny stocks' might seem outdated, these stocks continue to offer a unique blend of affordability and potential growth when backed by solid financials. In this article, we explore several penny stocks that stand out for their financial strength and potential as under-the-radar opportunities for investors.
NasdaqCM:AENT
NasdaqCM:AENTRetail Distributors

April 2026 US Undiscovered Gems with Promising Potential

The United States market has experienced a notable upswing, rising 3.6% in the past week and 39% over the last year, with earnings projected to grow by 16% annually in the coming years. In this dynamic environment, identifying stocks with strong fundamentals and growth potential can uncover promising opportunities often overlooked by mainstream investors.